| PARP inhibitors in prostate cancer–the preclinical rationale and current clinical development V Virtanen, K Paunu, JK Ahlskog, R Varnai, C Sipeky, M Sundvall Genes 10 (8), 565, 2019 | 59 | 2019 |
| More than meets the eye: scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer and … A Hyväkkä, V Virtanen, J Kemppainen, TJ Grönroos, H Minn, M Sundvall Cancers 13 (9), 2244, 2021 | 26 | 2021 |
| Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer V Virtanen, K Paunu, A Kukkula, S Niva, Y Junila, M Toriseva, T Jokilehto, ... Oncogenesis 12 (1), 42, 2023 | 5 | 2023 |
| Functionality of BRCA1 supports the survival of prostate cancer cells during the development of castration resistance S Sriraman, V Virtanen, A Kukkula, M Toriseva, A Rokka, A Lumiainen, ... bioRxiv, 2024.06. 19.599365, 2024 | | 2024 |
| Effect of caldesmon mutations in the development of zebrafish embryos V Virtanen, K Paunu, S Niva, M Sundvall, I Paatero Biochemical and Biophysical Research Communications 669, 10-18, 2023 | | 2023 |
| Abstract A024: Glucocorticoid receptor-induced non-muscle caldesmon regulates growth and metastasis in castration-resistant prostate cancer V Virtanen, K Paunu, A Kukkula, S Niva, Y Junila, M Toriseva, T Jokilehto, ... Cancer Research 83 (11_Supplement), A024-A024, 2023 | | 2023 |
| Uusia työkaluja paikallisesti edenneen ja etäpesäkkeisen eturauhassyövän lääkehoitoon V Virtanen, H Rautiola, M Poutanen, PJ Boström, H Minn, M Sundvall Lääketieteellinen Aikakauskirja Duodecim 136 (18), 2013-22, 2020 | | 2020 |
Réka VárnaiUniversity of Pécs Medical School在 pte.hu 的电子邮件经过验证
